Cargando…
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas
Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to identify those most likely to benefit from herceptin-targeted therapy. HER2 amplification, detected in 20-30% of invasive breast tumors, is associated with reduced survival and metastasis. The most freque...
Autores principales: | Rosa, F.E., Santos, R.M., Rogatto, S.R., Domingues, M.A.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Divulgação Científica
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854374/ https://www.ncbi.nlm.nih.gov/pubmed/23558859 http://dx.doi.org/10.1590/1414-431X20132483 |
Ejemplares similares
-
Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma
por: Rosa, Fabíola E, et al.
Publicado: (2009) -
Chromogenic in situ Hybridization Compared with Real time Quantitative Polymerase Chain Reaction to Evaluate HER2/neu Status in Breast Cancer
por: Ayatollahi, Hossein, et al.
Publicado: (2017) -
Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status
por: Madrid, Manuelito A, et al.
Publicado: (2004) -
Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma
por: Ali, Ali Hussein Mohammed, et al.
Publicado: (2019) -
HER-2/neu Oncogene Amplification by Chromogenic in situ Hybridization in 130 Breast Cancers Using Tissue Microarray and Clinical Follow-up Studies
por: Chang, Eundeok, et al.
Publicado: (2004)